Preparation and identification of anti-rubella virus neutralizing serum based on mRNA technology
10.13200/j.cnki.cjb.004647
- VernacularTitle:基于mRNA技术的抗风疹病毒中和血清制备及鉴定
- Author:
Meiyi ZHAO
1
Author Information
1. Shanghai Institute of Biological Products Co., Ltd., Shanghai 201403, China
- Publication Type:Journal Article
- Keywords:
Rubella virus(RuV);
E1 protein;
Neutralizing serum;
mRNA vaccine;
Idiosyncrasy
- From:
Chinese Journal of Biologicals
2026;39(02):217-221+228
- CountryChina
- Language:Chinese
-
Abstract:
Objective To prepare neutralizing serum against rubella virus(RuV) using mRNA technology and identify it, so as to apply it to the identification and virus titer detection of measles, mumps and rubella vaccine(MMR).Methods The mRNA lipid nanoparticle(LNP) vaccine expressing RuV BRDⅡ vaccine strain and 2B genotype wild strain E1 protein was constructed, and its expression in 293T cells was verified by Western blot and indirect immunofluorescence. Guinea pigs were immunized with two kinds of mRNA-LNP vaccines and live attenuated rubella vaccine separately to prepare antiserum. The indirect ELISA method was used to detect the specific IgG antibody titer of RuV E1 protein in the serum, and the micro-neutralization method was applied to determine the neutralizing antibody titer. Furthermore, the cross-interference effect of serum on mumpsvirusandmeaslesviruswasevaluated.Results TheparticlesizesofthetwomRNA-LNPvaccineswere71.69 and70.77 nm respectively, with the encapsulation efficiency of more than 85%, and the E1 protein could be effectively expressed in 293T cells. The E1 protein-specific IgG antibody titers and neutralizing antibody titers produced by guinea pigs immunized with the two mRNA-LNP vaccines were all significantly higher than those of guinea pigs immunized with the live attenuated rubella vaccine(F = 20. 38-37. 94 and 10. 63-21. 59, P < 0. 001 and < 0. 05,respectively). Additionally, the serum only specifically neutralized RuV, and had no cross-interference with measles virus and mumps virus.Conclusion Based on mRNA technology, a high-titer and high-specificity anti-RuV neutralizing serum was successfully prepared, which is suitable for the quality verification of MMR vaccines and provides a new strategy for the development of rubella vaccines.
